Halozyme Therapeutics, Inc. develops and commercializes drug-delivery technologies for subcutaneous administration of biologics and other injectable therapies. News about HALO commonly covers ENHANZE licensing agreements, Hypercon and Surf Bio hyperconcentration collaborations, partner product regulatory approvals, royalty-based revenue updates, and financial guidance.
The company also reports developments tied to its proprietary products Hylenex and XYOSTED, drug-device combination products using auto-injector technologies, and collaborations with pharmaceutical and biotechnology companies in oncology, inflammatory disease and other therapeutic areas.
Halozyme Therapeutics (HALO) priced an upsized private offering of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 on September 17, 2026.
The notes, offered to qualified institutional buyers under Rule 144A, carry semi-annual interest and mature on October 1, 2033. They are initially convertible at 7.1509 shares per $1,000, implying a conversion price of about $139.84, a 27.5% premium to the $109.68 closing share price. Halozyme granted a 13‑day option for up to an additional $200 million of notes and expects net proceeds of about $1.275 billion (or $1.471 billion if the option is fully exercised).
The company plans to spend approximately $162.5 million on capped call transactions with a cap price of about $208.39 and to use part of the proceeds to repurchase outstanding 2027 and 2028 convertible notes, with the remainder for general corporate purposes and potential future note repurchases.
Halozyme Therapeutics (HALO) plans to offer $1.05 billion of convertible senior notes due 2033 in a private Rule 144A placement to qualified institutional buyers.
The company expects to grant initial purchasers a 13-day option for up to an additional $150 million of notes. The unsecured notes will pay semi-annual interest, mature on October 1, 2033, and be convertible under specified conditions before April 1, 2033, and at any time thereafter until shortly before maturity. Halozyme plans to settle conversions in cash and, at its election, common stock, and intends to enter capped call transactions to reduce potential dilution. Net proceeds will fund the capped calls, repurchases of existing 2027 and 2028 convertible notes, and general corporate purposes.
Halozyme (HALO) will participate in three upcoming investor conferences in September 2026, featuring fireside chats and 1x1 investor meetings with its President and CEO and CFO.
Events include the Wells Fargo 21st Annual Healthcare Conference on September 9 at 12:45pm PT, the Morgan Stanley 24th Annual Global Healthcare Conference on September 15 at 4:45am PT, and the H.C. Wainwright 28th Annual Global Investment Conference on September 16 at 7:00am PT. A live audio webcast and 90-day replays will be available in the Investor Relations section of Halozyme’s website.
Halozyme Therapeutics (Nasdaq: HALO) announced the election of Dannielle Appelhans to its Board of Directors, effective August 18, 2026. She brings over 20 years of leadership in biotechnology and pharmaceuticals, with extensive experience in operations, manufacturing, and global supply chain management.
According to Halozyme, Appelhans currently serves as President and CEO of COUR Pharmaceuticals, where she led a strategic collaboration with Genentech with potential value of up to $1 billion. Her prior roles include CEO of Rubius Therapeutics and senior leadership positions at Novartis, including Chief Technical Officer of Novartis Gene Therapies overseeing development, manufacturing and supply chain, including the approved gene therapy Zolgensma. She holds advanced engineering and business degrees from MIT and a mechanical engineering degree from the University of Michigan.
Halozyme (Nasdaq: HALO) reported record second quarter 2026 results, with total revenue of $481.0 million, up 48% year-over-year, and royalty revenue of $307.7 million, up 50%. Adjusted EBITDA rose to $328.8 million from $225.5 million and GAAP diluted EPS increased to $1.90 from $1.33.
For full-year 2026, Halozyme raised guidance to total revenue of $1.835–$1.910 billion, royalty revenue of $1.220–$1.245 billion, adjusted EBITDA of $1.225–$1.280 billion, and Non-GAAP diluted EPS of $8.65–$9.00. The company signed five new ENHANZE and Hypercon agreements year-to-date and repurchased 4.8 million shares for $332.8 million in Q2 under its buyback programs.
Halozyme (Nasdaq: HALO) plans to release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, after the U.S. market close. The company will host a results conference call that day at 1:30 p.m. PT / 4:30 p.m. ET, with live access via pre-registration link and webcast replay available in the Investors section of its website.
Halozyme (Nasdaq: HALO) announced a global collaboration and license agreement with Incyte (Nasdaq: INCY) to develop additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody for mutCALR-expressing myeloproliferative neoplasms, using Halozyme's ENHANZE® drug delivery technology.
According to Halozyme, it will receive an upfront payment from Incyte, plus potential milestone payments and royalties on net sales of medicines using ENHANZE®. Incyte also receives an option to nominate up to two additional targets for use with ENHANZE®.
Halozyme (Nasdaq: HALO) appointed David Ramsay as President Drug Delivery, effective June 30, 2026. This is a newly created, enterprise-wide role.
Ramsay will drive growth of Halozyme's drug delivery technologies, set strategic priorities, and lead business development and alliance management, reporting to CEO Helen Torley.
Halozyme (Nasdaq: HALO) projects zero to minimal impact on its royalty revenue through at least 2035 from the newly released draft Medicare Drug Price Negotiation Program proposed rule. The company also projects no impact on its ability to sign new ENHANZE partnerships, supported by orphan drug protections and biosimilar-related provisions.
Halozyme (Nasdaq: HALO) reported strong Q1 2026 results and a new $1 billion share repurchase program, expecting at least $400 million of buybacks in 2026. Total revenue rose 42% year over year to $376.7 million, with royalty revenue up 43% to $240.7 million.
GAAP diluted EPS was $1.22 and non-GAAP diluted EPS $1.60. Halozyme reiterated 2026 guidance, including total revenue of $1.71-$1.81 billion, royalty revenue of $1.13-$1.17 billion, adjusted EBITDA of $1.125-$1.205 billion and non-GAAP EPS of $7.75-$8.25.